TG Therapeutics, Inc. (TGTX)

NCM – Real Time Price. Currency in USD

42.54

-0.60 (-1.39%)

At close: May 12, 2026, 4:00 PM EDT

42.57

+0.03 (0.07%)

Pre-market: May 13, 2026, 7:09 AM EDT

11.05.2026

Historic Signal Says This Biotech Outperforms

TG Therapeutics Inc (NASDAQ:TGTX) is trading down 1.2% at $42.35, after last week being rejected by the overhead $44 ceiling.

07.05.2026

TGTX Q1 Earnings Miss, Sales Rise Y/Y, Stock Up on Raised 2026 View

TG Therapeutics misses Q1 earnings estimates, but strong Briumvi sales drive y/y revenues. Shares rise as the company raises 2026 revenue outlook.

06.05.2026

TG Therapeutics, Inc. (TGTX) Q1 2026 Earnings Call Transcript

06.05.2026

TG Therapeutics (TGTX) Q1 Earnings Lag Estimates

TG Therapeutics (TGTX) came out with quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.03 per share a year ago.

06.05.2026

TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance

First quarter 2026 total global revenue of approximately $205 million, including BRIUMVI U.S. net revenue of approximately $195 million Raises full year 2026 total global revenue target to approximately $925 million and raises full year 2026 BRIUMVI U.S. net product revenue target to $885-900 million Conference call to be held today, Wednesday, May 6, 2026, at 8:30 AM ET NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the first quarter of 2026, along with recent company developments and provided an update on 2026 financial guidance. Michael S.

30.04.2026

TG Therapeutics to Host Conference Call on First Quarter 2026 Financial Results and Business Update

NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Wednesday, May 6, 2026, at 8:30 AM ET to discuss results for the first quarter 2026 and to provide a business outlook for the remainder of 2026. Michael S.

28.04.2026

Fortrea Holdings Inc. (FTRE) Reports Next Week: Wall Street Expects Earnings Growth

Fortrea Holdings Inc. (FTRE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Videos

No Data

There is no data to display

Press releases

06.05.2026

TG Therapeutics, Inc. (TGTX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

TG Therapeutics, Inc. (TGTX)

Historic Signal Says This Biotech Outperforms

TGTX Q1 Earnings Miss, Sales Rise Y/Y, Stock Up on Raised 2026 View

TG Therapeutics, Inc. (TGTX) Q1 2026 Earnings Call Transcript

TG Therapeutics (TGTX) Q1 Earnings Lag Estimates

TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance

TG Therapeutics to Host Conference Call on First Quarter 2026 Financial Results and Business Update

Fortrea Holdings Inc. (FTRE) Reports Next Week: Wall Street Expects Earnings Growth

Videos

No Data

Press releases

TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance

Historic Signal Says This Biotech Outperforms

TGTX Q1 Earnings Miss, Sales Rise Y/Y, Stock Up on Raised 2026 View

TG Therapeutics, Inc. (TGTX) Q1 2026 Earnings Call Transcript

TG Therapeutics (TGTX) Q1 Earnings Lag Estimates

TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance

TG Therapeutics to Host Conference Call on First Quarter 2026 Financial Results and Business Update

Fortrea Holdings Inc. (FTRE) Reports Next Week: Wall Street Expects Earnings Growth

Videos

No Data

Press releases

TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance

TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI

TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million

Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis

Search stocks

TG Therapeutics, Inc. (TGTX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

TG Therapeutics, Inc. (TGTX)

Historic Signal Says This Biotech Outperforms

TGTX Q1 Earnings Miss, Sales Rise Y/Y, Stock Up on Raised 2026 View

TG Therapeutics, Inc. (TGTX) Q1 2026 Earnings Call Transcript

TG Therapeutics (TGTX) Q1 Earnings Lag Estimates

TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance

TG Therapeutics to Host Conference Call on First Quarter 2026 Financial Results and Business Update

Fortrea Holdings Inc. (FTRE) Reports Next Week: Wall Street Expects Earnings Growth

Videos

No Data

Press releases

TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance

Historic Signal Says This Biotech Outperforms

TGTX Q1 Earnings Miss, Sales Rise Y/Y, Stock Up on Raised 2026 View

TG Therapeutics, Inc. (TGTX) Q1 2026 Earnings Call Transcript

TG Therapeutics (TGTX) Q1 Earnings Lag Estimates

TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance

TG Therapeutics to Host Conference Call on First Quarter 2026 Financial Results and Business Update

Fortrea Holdings Inc. (FTRE) Reports Next Week: Wall Street Expects Earnings Growth

Videos

No Data

Press releases

TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance

TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI

TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million

Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis